The deal – financial terms of which were not disclosed – will see the Danish supplier take over management of Allopartis from the renewable energy-focused venture capital fund, CalCEF Clean Energy Angel.
In addition to it biofuel business, San Francisco, US-based Allopartis also uses its enzyme optimisation knowhow to develop biological catalysts for other industries, including the biopharmaceutical sector.
Ejner Bech Jensen, Vice President, Research and Development, Novozymes said: “Novozymes looks forward to integrate and implement Allopartis’ promising evolution and screening methods into our efforts within the discovery of new and better enzymes.
“The three founders have demonstrated strong competencies during their built-up of Allopartis and we are pleased to welcome them to Novozymes.”
This was echoed by Novozymes spokesman Rene Tronborg who told BioPharma-reporter.com that Allopartis provides a "technology base which can be used for evolution of enzymes, and Novozymes’ focus is better performing enzymes for industrial use.
"In short: Allopartis is a biotech company located in San Francisco; it has developed a technology platform that develops optimized enzymes and other proteins. Also, Allopartis’ technology allows Novozymes to screen larger enzyme libraries and hereby increasing our chances to identify even better enzymes for industrial use."